Ian D Davis

Summary

Affiliation: Ludwig Institute for Cancer Research
Country: Australia

Publications

  1. ncbi request reprint Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma
    Geoffrey Chong
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 11:4818-26. 2005
  2. ncbi request reprint Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
    Ian D Davis
    Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    J Immunother 29:499-511. 2006
  3. pmc A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:13. 2007
  4. pmc A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:14. 2007
  5. ncbi request reprint An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma
    Ian D Davis
    Austin Health, Melbourne, Victoria, Australia
    Clin Cancer Res 13:3630-6. 2007
  6. ncbi request reprint Interleukin-21 signaling: functions in cancer and autoimmunity
    Ian D Davis
    Ludwig Austin Joint Medical Oncology Unit, Austin Health, Melbourne, Australia
    Clin Cancer Res 13:6926-32. 2007
  7. ncbi request reprint Rational approaches to human cancer immunotherapy
    Ian D Davis
    Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia
    J Leukoc Biol 73:3-29. 2003
  8. ncbi request reprint Clinical use of therapies targeting tumor vasculature and stroma
    Ian D Davis
    Austin Hospital and Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    Curr Cancer Drug Targets 8:498-508. 2008
  9. ncbi request reprint A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy
    Ian D Davis
    Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    Clin Cancer Res 11:1890-8. 2005
  10. ncbi request reprint An overview of cancer immunotherapy
    I D Davis
    Ludwig Institute for Cancer Research, Austin Repat Cancer Centre, Heidelberg, Victoria, Australia
    Immunol Cell Biol 78:179-95. 2000

Detail Information

Publications81

  1. ncbi request reprint Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma
    Geoffrey Chong
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 11:4818-26. 2005
    ..Three patients were treated at 20, 30, and 40 mCi/m2 dose levels, and six patients at 50 mCi/m2 to define the maximum tolerated dose...
  2. ncbi request reprint Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
    Ian D Davis
    Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    J Immunother 29:499-511. 2006
    ..MAGE-A10-specific T cells with a skewed T-cell receptor repertoire were detected in 1 patient in blood ex vivo and from tumor biopsies. Vaccination with FLDCs pulsed with peptides is safe and primes immune responses to cancer antigens...
  3. pmc A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:13. 2007
    ..In conclusion, repeated intravenous doses of up to 50 mg/m(2) of cG250 are safe. Furthermore cG250 has a long half-life and targets clear cell RCC effectively...
  4. pmc A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:14. 2007
    ..No antitumour responses were observed. In conclusion, weekly cG250 with daily low-dose subcutaneous IL-2 is well tolerated. IL-2 does not influence cG250 biodistribution or increase HACA...
  5. ncbi request reprint An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma
    Ian D Davis
    Austin Health, Melbourne, Victoria, Australia
    Clin Cancer Res 13:3630-6. 2007
    ....
  6. ncbi request reprint Interleukin-21 signaling: functions in cancer and autoimmunity
    Ian D Davis
    Ludwig Austin Joint Medical Oncology Unit, Austin Health, Melbourne, Australia
    Clin Cancer Res 13:6926-32. 2007
    ..Recently conducted phase 1 trials in metastatic melanoma and renal cell carcinoma have shown that recombinant IL-21 has a favorable safety profile and support its continued investigation as a potential anticancer drug...
  7. ncbi request reprint Rational approaches to human cancer immunotherapy
    Ian D Davis
    Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia
    J Leukoc Biol 73:3-29. 2003
    ..The beginning of the 21st century brings the possibility of a new era of effective cancer immunotherapy, combining rational, immunological treatments with conventional therapies to improve the outcome for patients with cancer...
  8. ncbi request reprint Clinical use of therapies targeting tumor vasculature and stroma
    Ian D Davis
    Austin Hospital and Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    Curr Cancer Drug Targets 8:498-508. 2008
    ..Treatments directed at these interactions bring new challenges in terms of how best to develop these strategies, and require approaches that differ in many ways from conventional anticancer therapies...
  9. ncbi request reprint A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy
    Ian D Davis
    Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    Clin Cancer Res 11:1890-8. 2005
    ....
  10. ncbi request reprint An overview of cancer immunotherapy
    I D Davis
    Ludwig Institute for Cancer Research, Austin Repat Cancer Centre, Heidelberg, Victoria, Australia
    Immunol Cell Biol 78:179-95. 2000
    ..At the same time, it is possible to recruit other aspects of the immune system, both specific (e.g. antibody responses) and innate (natural killer cells and granulocytes)...
  11. ncbi request reprint A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer
    I D Davis
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Growth Factors 17:287-300. 2000
    ..To investigate the pharmacokinetics and tolerability of recombinant human interleukin-4 (rhuIL-4), administered by daily subcutaneous injection, in patients with advanced cancer...
  12. pmc Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
    Ian D Davis
    Ludwig Institute for Cancer Research, Melbourne 3084, Australia
    Proc Natl Acad Sci U S A 101:10697-702. 2004
    ..In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically...
  13. ncbi request reprint The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
    Mark Shackleton
    Cancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, Australia
    Cancer Immun 4:9. 2004
    ..FL treatment of melanoma patients has pleiotropic clinical and hematological effects. In vivo maturation of FL-generated DCs using imiquimod may increase immune responses to tumor antigens...
  14. doi request reprint Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma
    Theo Nicholaou
    Ludwig Institute for Cancer Research, Austin Health, Peter MacCallum Cancer Centre, CSL Limited, Melbourne, Victoria, Australia
    Clin Cancer Res 15:2166-73. 2009
    ..This study examines the clinical and immunologic efficacy of the same vaccine in patients with advanced metastatic melanoma...
  15. doi request reprint Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
    Craig Gedye
    Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg, Vic, 3084, Australia
    Cancer Immunol Immunother 58:1635-46. 2009
    ..Our in vitro findings raise the hypothesis that if melanoma stem cells express CT antigens in vivo that immune targeting of these antigens may be a viable clinical strategy for the adjuvant treatment of melanoma...
  16. doi request reprint Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4
    Oliver Klein
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Heidelberg, Victoria, Australia
    Clin Cancer Res 15:2507-13. 2009
    ..Although these reactions are believed to be immune-mediated, the antigenic targets for the cellular or humoral immune response are not known...
  17. doi request reprint Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™
    Theo Nicholaou
    Ludwig Institute for Cancer Research, Melbourne, Austin Hospital, Heidelberg, Vic, Australia
    Cancer Immunol Immunother 60:1625-37. 2011
    ..We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated in an earlier trial...
  18. ncbi request reprint Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli
    Michael Jefford
    Ludwig Institute Oncology Unit, Austin and Repatriation Medical Centre, Studley Rd, Heidelberg, Victoria 3084, Australia
    Blood 102:1753-63. 2003
    ..These distinct differences are of particular importance when considering the choice of DC types for clinical applications...
  19. ncbi request reprint Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination
    Qiyuan Chen
    Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    Cancer Immun 5:5. 2005
    ..The demonstrated presence of antigen-specific T cells at vaccination sites validates this method of assessing the immune response to i.d. vaccines...
  20. ncbi request reprint Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery
    Max Schnurr
    Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria, Australia
    Blood 105:2465-72. 2005
    ..This may provide DCs with ample opportunities for sensitizing tumor-specific T cells against a broad array of tumor antigen epitopes in lymph nodes...
  21. doi request reprint A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design
    Lisa M Ebert
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia
    Cancer Res 69:1046-54. 2009
    ..Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design...
  22. ncbi request reprint A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples
    Heather M Jackson
    Ludwig Institute for Cancer Research, Melbourne Branch, Austin Health, Heidelberg VIC 3084, Australia
    J Immunol Methods 291:51-62. 2004
    ....
  23. ncbi request reprint Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1
    Heather Jackson
    Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    J Immunol 176:5908-17. 2006
    ..The pattern of anti-NY-ESO-1 T cell responses in this patient closely resembles the classical broad yet hierarchical antiviral immunity and was confirmed in a second subject...
  24. pmc Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
    Qiyuan Chen
    Ludwig Institute for Cancer Research, Austin Health, 145 163 Studley Road, Heidelberg, Victoria 3084, Australia
    Proc Natl Acad Sci U S A 101:9363-8. 2004
    ..This T cell response was vaccinated in most patients who expressed HLA-DR2. This study has systematically surveyed patients vaccinated with full-length tumor antigen for a vaccinated CD4 helper T cell response...
  25. ncbi request reprint Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens
    Elgene Lim
    Ludwig Institute for Cancer Research Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
    Melanoma Res 16:347-55. 2006
    ..Low levels of expression of cancer testis antigen may indicate that they are suboptimal targets for vaccine development in desmoplastic melanoma...
  26. ncbi request reprint A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Australia
    Clin Cancer Res 13:3286-92. 2007
    ..We report a first-in-man trial of a humanized antibody (hu3S193) against the Le(y) antigen...
  27. doi request reprint Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT
    Nathan Lawrentschuk
    University of Melbourne Department of Surgery, Austin Hospital, Melbourne, Victoria, Australia
    Urol Oncol 29:411-20. 2011
    ....
  28. ncbi request reprint Tumor antigen expression in melanoma varies according to antigen and stage
    Catherine Barrow
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 12:764-71. 2006
    ..Obtaining a detailed understanding of antigen expression in primary and metastatic melanoma is essential if these molecules are to be useful targets for immunotherapy of melanoma...
  29. doi request reprint Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects
    Oliver Klein
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Heidelberg, Victoria, Australia
    Eur J Immunol 43:533-9. 2013
    ..On the basis of these findings, Flt3L may represent a promising agent for promoting immune tolerance in a variety of clinical settings...
  30. doi request reprint Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans
    Joe H Chang
    Radiation Oncology Centre, Austin Health, Victoria, Australia
    Int J Radiat Oncol Biol Phys 83:e691-6. 2012
    ..To demonstrate the technical feasibility of intensity modulated radiation therapy (IMRT) dose painting using (11)C-choline positron emission tomography PET scans in patients with localized prostate cancer...
  31. pmc Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Centre for ClinicalSciences, Austin Hospital, Heidelberg, Victoria, Australia
    Prostate 69:92-104. 2009
    ..The ability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 and docetaxel chemotherapy to enhance the efficacy of RIT was also assessed in vivo...
  32. ncbi request reprint Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1
    Theo Nicholaou
    Ludwig Institute for Cancer Research, Cancer Vaccine Programme, Austin Hospital, Victoria, Australia
    Immunol Cell Biol 84:303-17. 2006
    ..These early studies have yielded a wealth of information about the immunology of NY-ESO-1 and set the scene for future clinical strategies for immune targeting of cancer...
  33. ncbi request reprint Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011
    Sue M Evans
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Med J Aust 198:540-5. 2013
    ..To describe patterns of care for men diagnosed with prostate cancer in Victoria, Australia, between 2008 and 2011...
  34. ncbi request reprint Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma
    Jonathan Cebon
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Cancer Immun 3:7. 2003
    ..The rhIL-12 given either s.c. or i.v. was well tolerated at doses of 10-100 ng/kg. Clinical and immunological activity has been observed in this study where peptides were administered either with or without low dose rhIL-12...
  35. ncbi request reprint Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Heidelberg, Victoria, 3084, Australia
    Cancer Immun 5:3. 2005
    ..The favourable immune properties of KM871, combined with this preliminary clinical data, indicate that KM871 has potential for the treatment of metastatic melanoma...
  36. doi request reprint Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate
    Suzanne Svobodova
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Vic, Australia
    Eur J Cancer 47:460-9. 2011
    ..In view of these results, further investigation of the function of CTAgs and their potential use in therapeutic targeting is warranted...
  37. doi request reprint The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells
    Lisa M Ebert
    Ludwig Institute for Cancer Research Melbourne Center for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia
    Cancer Res 68:3001-9. 2008
    ..Together, our results show that FoxP3, a key regulator of immune suppression, is not only expressed by Treg but also by melanoma cells, EBV-transformed B cells, and a wide variety of tumor cell lines...
  38. doi request reprint Predicting clinical outcome through molecular profiling in stage III melanoma
    Thomas John
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Australia
    Clin Cancer Res 14:5173-80. 2008
    ..We hypothesized that molecular profiling could be used to identify prognostic groups within patients with stage III melanoma while also providing a greater understanding of the biological programs underpinning these differences...
  39. pmc A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma
    Lisa M Ebert
    Ludwig Institute for Cancer Research Melbourne Austin Branch, Melbourne, Australia
    PLoS ONE 7:e48424. 2012
    ....
  40. doi request reprint Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy
    Joe H Chang
    Radiation Oncology Centre, Austin Health, Victoria, Australia
    Radiother Oncol 99:187-92. 2011
    ..To evaluate the accuracy of (11)C-choline PET scans in defining dominant intraprostatic lesions (DILs) for radiotherapy target volume definition...
  41. ncbi request reprint Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells
    Max Schnurr
    Ludwig Institute Oncology Unit, Melbourne Tumour Biology Branch, Austin and Repatriation Medical Centre, Studley Rd, Heidelberg, Victoria 3084, Australia
    Blood 103:1391-7. 2004
    ....
  42. doi request reprint Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial
    Ian D Davis
    Ludwig Oncology Unit, Austin Health, Melbourne, Victoria, Australia
    Clin Cancer Res 15:2123-9. 2009
    ..We report final clinical and biological results of a phase II study of recombinant human IL-21 (rIL-21) in patients with metastatic melanoma...
  43. ncbi request reprint Xenografting tumour beneath the renal capsule using modern surgical equipment
    Nathan Lawrentschuk
    Department of Surgery and Urology, Tumour Targetting Laboratory, Austin Hospital, Heidelberg, Vic, Australia
    Eur Surg Res 38:340-6. 2006
    ..We report on a novel method for human renal tumour transplants using an automated biopsy gun to obtain tumour tissue and an epidural needle with introducer to easily deploy the grafts under the renal capsule...
  44. ncbi request reprint Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1
    Hilary A Vaughan
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 10:8396-404. 2004
    ..This study evaluates typing strategies used to distinguish these two homologous but distinct antigens and to characterize and quantitate expression of each in clinical samples...
  45. ncbi request reprint Immunotherapy of advanced or metastatic melanoma
    Jonathan Cebon
    University of Melbourne, Ludwig Institute for Cancer Research, Center for Clinical Sciences at the Austin Hospital, Heidelberg, VIC 3084, Australia
    Clin Adv Hematol Oncol 5:994-1006. 2007
    ..New therapeutic strategies are resulting from these emerging insights into the relationship between melanoma and the host immune response...
  46. doi request reprint Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile
    Matthew Anaka
    Cancer Immuno biology Lab, Ludwig Institute for Cancer Research, Melbourne Austin Branch, Melbourne, Victoria, Australia
    Stem Cells 30:336-43. 2012
    ..In conclusion, SCM culture of melanoma does not provide a better representation of the phenotype or genotype of metastatic melanoma, and the resulting neural bias could potentially confound therapeutic target identification...
  47. ncbi request reprint A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer
    Michael Jefford
    Centre for Developmental Cancer Therapeutics, Melbourne, Victoria, Australia
    Invest New Drugs 22:185-92. 2004
    ..We conducted a dose escalation study combining cisplatin, irinotecan, and capecitabine (CIC), aiming to establish the maximum tolerated doses (MTD), side effect profile, and dose-limiting toxicity (DLT) of this novel regimen...
  48. ncbi request reprint Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Victoria, Australia
    BJU Int 96:540-6. 2005
    ....
  49. ncbi request reprint Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation
    T Luft
    Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    J Immunol 167:2529-37. 2001
    ..These findings have implications for the design of peptide and protein-based vaccines...
  50. doi request reprint ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer
    Thomas John
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Victoria, Australia
    Clin Cancer Res 14:3291-8. 2008
    ..We hypothesized that ECSA/DPPA2 would be quiescent in most normal tissues but expressed in cancers and may therefore be a useful target for immunotherapy...
  51. pmc A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen
    Rona Y Zhao
    Ludwig Institute for Cancer Research, Melbourne Austin Branch, Austin Health, Heidelberg, Victoria, Australia
    PLoS ONE 7:e44707. 2012
    ..The potential implications for cancer vaccine strategies are further discussed...
  52. doi request reprint A novel method for detecting antigen-specific human regulatory T cells
    Lisa M Ebert
    Ludwig Institute for Cancer Research Melbourne Austin Branch, Melbourne, Australia
    J Immunol Methods 377:56-61. 2012
    ..Culture conditions and re-stimulation time have been optimized, allowing the detection of even very rare Treg, such as those specific to tumor antigens...
  53. ncbi request reprint Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel
    Michael Jefford
    Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Victoria, Australia
    ANZ J Surg 74:704-5. 2004
    ..The pattern of disease in the reported patient was similar to that described in the literature, but the patient experienced a long period with untreated metastatic disease compared with that in the literature...
  54. ncbi request reprint Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice
    Nathan Lawrentschuk
    University of Melbourne, Department of Surgery, Victoria, Australia
    Int J Urol 14:89-95. 2007
    ..This article summarizes the current diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer with particular reference to radionuclide bone scintigraphy and positron emission tomography...
  55. doi request reprint Melanoma vaccines: developments over the past 10 years
    Oliver Klein
    Ludwig Institute for Cancer Research, Austin Branch, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
    Expert Rev Vaccines 10:853-73. 2011
    ..Long-term therapeutic control of melanoma will require integration of specific active immunotherapy with these emerging successful therapies from the disparate fields of immune regulation and signal transduction...
  56. doi request reprint Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
    Mathis Grossmann
    Endocrine Unit, Austin Health, Victoria, Australia
    Clin Endocrinol (Oxf) 69:669-72. 2008
    ..Hypothyroidism has been observed in patients treated with sunitinib, but the mechanism whereby sunitinib induces hypothyroidism is unknown...
  57. ncbi request reprint Targeted therapies in the treatment of renal cell carcinoma
    Carmel Pezaro
    Ludwig Institute Oncology Unit, Austin Health, Melbourne, Victoria, Australia
    Curr Med Chem 15:1166-74. 2008
    ..This review summarizes the major published clinical trials of the new agents, discusses the controversies and research questions that have arisen as a result, and considers some of the issues that remain...
  58. ncbi request reprint A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors
    Hui K Gan
    Department of Medical Oncology and Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Melbourne, Vic, Australia
    Cancer Chemother Pharmacol 58:157-64. 2006
    ..This schedule may maximize dose intensity of both drugs with acceptable or reduced toxicity...
  59. ncbi request reprint Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Australia
    BJU Int 97:916-22. 2006
  60. ncbi request reprint Positron emission tomography and molecular imaging of the prostate: an update
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Australia
    BJU Int 97:923-31. 2006
  61. ncbi request reprint A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35
    Q Chen
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Repat Cancer Centre, Heidelberg, Vic, Australia
    Melanoma Res 10:16-25. 2000
    ..Since it is difficult to predict the CTL responses to Melan-A peptide in a given individual, we suggest vaccinating with both Melan-A27-35 and Melan-A26-35 peptides in clinical trials...
  62. ncbi request reprint The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium
    M Saleh
    Neuroscience Centre, Department of Surgery and Neurosurgery, The University of Melbourne, Victoria, Australia
    Int J Cancer 72:664-72. 1997
    ..Our results suggest that mIL-4 has bimodal biological roles in potentiating tumour inhibition in athymic mice: the suppression of angiogenesis and the augmentation of the host local immune response...
  63. ncbi request reprint Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions
    R Murphy
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Heidelberg, Australia
    Prep Biochem Biotechnol 35:119-34. 2005
    ..The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A...
  64. ncbi request reprint The use of dendritic cells in cancer therapy
    M Jefford
    Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia
    Lancet Oncol 2:343-53. 2001
    ..This paper reviews the biology of dendritic cells and their use in clinical trials, as well as highlighting issues for future trial design...
  65. doi request reprint Oncology health information quality on the Internet: a multilingual evaluation
    Nathan Lawrentschuk
    Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
    Ann Surg Oncol 19:706-13. 2012
    ..We compared the quality of common malignancy Web sites to assess them for language or disease differences and to perform a quality comparison between medical and layperson terminology...
  66. ncbi request reprint Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma
    Marion T Harris
    Centre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australia
    Mol Imaging Biol 7:304-8. 2005
    ....
  67. ncbi request reprint ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling
    Max Schnurr
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin, Australia
    Blood 102:613-20. 2003
    ..P2R inhibition may represent a new strategy to improve the migration of antigen-loaded DCs from the vaccination site to lymph nodes...
  68. doi request reprint The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer
    Sue M Evans
    Centre of Research Excellence in Patient Safety, Monash University, Melbourne, Australia
    BJU Int 111:E158-66. 2013
    ..To establish a pilot population-based clinical registry with the aim of monitoring the quality of care provided to men diagnosed with prostate cancer...
  69. doi request reprint Urothelial cancers: using biology to improve outcomes
    Carmel Pezaro
    Joint Ludwig Austin Oncology Unit, Austin Hospital LTB6, Heidelberg, VIC 3084, Australia
    Expert Rev Anticancer Ther 12:87-98. 2012
    ..We will consider evidence for the current systemic therapies for muscle-invasive and metastatic disease and review the targeted therapies under investigation for advanced urothelial cancer...
  70. doi request reprint Cancer stem cells in urologic cancers
    Craig Gedye
    Department of Medicine, Melbourne University, Austin Health, Studley Road, Heidelberg, Australia
    Urol Oncol 28:585-90. 2010
    ....
  71. doi request reprint Peripheral primitive neuroectodermal tumor arising from the seminal vesicle
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Austin Hospital, Heidelberg, Vic, Australia
    Urol Int 80:212-5; discussion 216. 2008
    ..It is essential that unusual tumors are considered when confronted by a seminal vesicle mass and that appropriate investigation and management are initiated...
  72. doi request reprint Breast and prostate cancer: more similar than different
    Gail P Risbridger
    Department of Anatomy and Developmental Biology, Monash University Clayton Campus, Melbourne 3800, Victoria, Australia
    Nat Rev Cancer 10:205-12. 2010
    ..In this Opinion article we discuss some key issues common to breast and prostate cancer and how new insights into these cancers could improve patient outcomes...
  73. ncbi request reprint Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial
    A M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, and Department of Nuclear Medicine and Centre for Positron Emission Tomography, Surgery, and Anatomical Pathology, Melbourne, Australia
    J Clin Oncol 19:3976-87. 2001
    ..KM871 is a chimeric monoclonal antibody against the ganglioside antigen GD3, which is highly expressed on melanoma cells. We conducted an open-label, dose escalation phase I trial of KM871 in patients with metastatic melanoma...
  74. ncbi request reprint A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours
    P L R Mitchell
    Centre for Developmental Cancer Therapeutics at Austin and Repatriation Medical Centre, Western Hospital and Royal Melbourne Hospital, Melbourne, Victoria, Australia
    Ann Oncol 14:788-94. 2003
    ..The objectives of this study were to determine the maximum tolerated dose (MTD) and toxicity profile of docetaxel given with G-CSF support...
  75. ncbi request reprint 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy
    L Johns Putra
    Department of Surgery, University of Melbourne, Melbourne, Australia
    Urology 64:1202-7. 2004
    ..To evaluate the role of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in the assessment of germ cell tumors after chemotherapy...
  76. ncbi request reprint Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma
    Malcolm Ranson
    Department of Medical Oncology, University of Manchester, United Kingdom
    J Clin Oncol 25:2540-5. 2007
    ....
  77. ncbi request reprint A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer
    Dishan H Gunawardana
    Centre for Developmental Cancer Therapeutics, Parkville, Victoria 3050, Australia
    Clin Cancer Res 9:2056-65. 2003
    ..We aimed to examine the safety, pharmacokinetics, and biological effects of recombinant human LIF (rhLIF, emfilermin) in patients with advanced cancer...
  78. pmc IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma
    Klaus Stensgaard Frederiksen
    Novo Nordisk A S, Novo Nordisk Park, Maalov, Denmark
    Cancer Immunol Immunother 57:1439-49. 2008
    ..Here we report the effects of systemic IL-21 therapy on the immune system in two phase 1 trials with this novel cytokine...
  79. ncbi request reprint Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy
    Lee S Rosen
    Premiere Oncology, John Wayne Cancer Institute, St John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 24:5194-200. 2006
    ....
  80. doi request reprint Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer
    John R Zalcberg
    J Clin Oncol 26:1386-7. 2008
  81. ncbi request reprint Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate
    Theo Nicholaou
    Lancet 369:1923-4. 2007